Regentis Biomaterials Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Regentis Biomaterials Ltd. (RGNT) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income4.80-4.13-1.45-5.14-0.41
Change in Working Capital-1.600.71-0.120.85-0.27
Change in Accounts Payable-1.360.25-0.021.22-0.09
Change in Other Working Capital-3.312.190.404.46-0.18
Other Operating Activities-3.312.190.404.460.14
Net Cash from Operating Activities-0.64-1.22-1.500.13-0.54
Investing Activities
Net Cash from Investing Activities0.000.000.000.000.00
Financing Activities
Debt Repayment-0.330.000.000.000.00
Net Cash from Financing Activities0.530.330.001.240.50
Summary
Net Change in Cash-0.12-0.90-1.501.37-0.04
Cash at Beginning of Period0.351.242.741.380.00
Cash at End of Period0.230.351.242.740.00
Free Cash Flow-0.64-1.22-1.500.130.00